Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vor Biopharma Inc (NQ: VOR )

0.8388 +0.0488 (+6.18%)
Streaming Delayed Price Updated: 10:48 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vor Biopharma Inc

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Vor Biopharma reveals promising Phase 1/2 study results for AML treatment, and it is planning FDA pivotal trial discussions. 
Via Benzinga
Exposures Product Safety
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Vor Biopharma: Q4 Earnings Insights
Via Benzinga
The Latest Analyst Ratings for Vor Biopharma
Via Benzinga
What 11 Analyst Ratings Have To Say About Vor Biopharma
Via Benzinga
VOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024
VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
VOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024
VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
Although speculation can be bad for your blood pressure, these compelling penny stocks have some strong endorsements. 
Via InvestorPlace
VOR Stock Earnings: Vor Biopharma Beats EPS for Q4 2023
VOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
8 Analysts Have This to Say About Vor Biopharma
Via Benzinga
Vor Biopharma: Q1 Earnings Insights
Via Benzinga
Where Vor Biopharma Stands With Analysts
Via Benzinga
Truist Securities Maintains Buy Rating for Vor Biopharma: Here's What You Need To Know
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 647 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 128 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During the Friday's sesion, 157 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday's session saw 43 companies set new 52-week lows. 
Via Benzinga
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Vor Bio's Trem-cel Shows Early Encouraging Data In Leukemia Patients
Vor Biopharma Inc (NASDAQ: VOR) presented updated data from patients treated in the VBP101 Phase 1/2a study of trem-cel (formerly VOR33) in  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
Dow Rises 50 Points; Oxford Industries Shares Plunge
U.S. stocks pared some losses toward the end of trading, with the Dow Jones and S&P 500 turning higher on Friday. The Dow traded up 0.16% to 32,156.53 while the NASDAQ fell 0.16% to 11,768.17. The S&P... 
Via Benzinga
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Near Intelligence Inc. (NASDAQ: NIR) shares climbed 53.1% to $16.50. 
Via Benzinga
Vor Biopharma's Leukemia Cell Exhibits Favorable Engraftment Five Months Post-Transplant
Via Benzinga
Analyzing Vor Biopharma's Short Interest
Vor Biopharma's (NASDAQ:VOR) short percent of float has fallen 58.58% since its last report. The company recently reported that it has 2.53 million shares sold short, which is 5.31% of all regular... 
Via Benzinga
Dow Edges Higher; Prometheus Biosciences Shares Jump
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 0.5% on Wednesday. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.